Addex Therapeutics Files 6-K, Incorporates Exhibits
Ticker: ADXN · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1574232
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
Addex Therapeutics filed a 6-K on 9/30/25, incorporating prior exhibits into its F-3 and S-8 filings.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on September 30, 2025, reporting on its activities as of June 30, 2025. The filing incorporates by reference exhibits 99.1 and 99.2 into its existing registration statements on Form F-3 and Form S-8.
Why It Matters
This filing updates the SEC on Addex Therapeutics' ongoing reporting requirements and incorporates previously issued documents into its public filings.
Risk Assessment
Risk Level: low — This is a routine reporting form (6-K) that incorporates previously filed information, not a filing announcing new material events or financial results.
Key Numbers
- 20250630 — Period of Report (The filing covers activities up to this date.)
- 20250930 — Filing Date (The report was filed on this date.)
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- 001-39179 (company) — SEC File Number
- 333-255089 (company) — Form F-3 Registration Number
- 333-255124 (company) — Form S-8 Registration Number
- 333-272515 (company) — Form S-8 Registration Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the company has made or is required to make public in its home country, has filed or is required to file with a stock exchange, or has distributed or is required to distribute to its security holders.
What specific registration statements are being updated by this filing?
Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) and the registration statements on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd.
What is the principal executive office address for Addex Therapeutics Ltd.?
The principal executive offices are located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
What is the SIC code for Addex Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Does Addex Therapeutics file annual reports under Form 20-F or 40-F?
Addex Therapeutics indicates it files annual reports under cover of Form 20-F.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 14.3 · Accepted 2025-09-30 06:01:20
Filing Documents
- adxn-20250630x6k.htm (6-K) — 28KB
- adxn-20250630xex99d1.htm (EX-99.1) — 1966KB
- adxn-20250630xex99d2.htm (EX-99.2) — 257KB
- adxn-20250630xex99d3.htm (EX-99.3) — 91KB
- adxn-20250630xex99d3001.jpg (GRAPHIC) — 6KB
- 0001104659-25-094663.txt ( ) — 9389KB
- adxn-20250630.xsd (EX-101.SCH) — 82KB
- adxn-20250630_cal.xml (EX-101.CAL) — 94KB
- adxn-20250630_def.xml (EX-101.DEF) — 272KB
- adxn-20250630_lab.xml (EX-101.LAB) — 535KB
- adxn-20250630_pre.xml (EX-101.PRE) — 459KB
- adxn-20250630xex99d1_htm.xml (XML) — 1971KB
RISK FACTORS
RISK FACTORS Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on May 15, 2025. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd By: /s/ Tim Dyer Name: Tim Dyer Date: September 30, 2025 Title: Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 : Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.2 :
Management's Discussion and Analysis of Financial Condition and Result of Operations
Management's Discussion and Analysis of Financial Condition and Result of Operations Exhibit 99.3 : Press Release dated September 30, 2025 101.INS The following materials from this Report on Form 6-K are formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024; (ii) Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and the six-month periods ended June 30, 2025 and 2024; (iii) Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the six-month periods ended June 30, 2025 and 2024; (iv) Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the three-month periods ended June 30, 2025 and 2024; (v) Unaudited Interim Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2025 and 2024; and (vi) Unaudited Notes to the Interim Condensed Consolidated Financial Statements for the three-month and six-month periods ended June 30, 2025. 4